

PATENT
Attorney Docket No. P-162-US1
Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Number: U.S. 7,317,102 B2)
Application No.: 10/813,745) Confirmation Number: 5848
Issue Date: January 8, 2008)
Inventor(s): Mathai MAMMEN et al.)
Title: DIARYLMETHYL AND RELATED)
COMPOUNDS)

REQUEST FOR CERTIFICATE OF CORRECTION

ATTN: Certificate of Correction Branch

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Assignee of record hereby requests that the Director issue a certificate of correction for the above-identified patent to correct one or more mistakes. The requested corrections are shown on the attached Form PTO/SB/44 (1 page).

A. Requested Corrections

A certificate of correction is requested to correct the following mistakes:

a. Office Mistakes – 37 C.F.R. §1.322

- (1) In column 103, at line 17, delete “of any one” (shown correctly at page 4, line 2, of the Amendment filed on April 19, 2007).

- (2) In column 103, at line 27, “-(CH²)₈-” should read “-(CH₂)₈-” (shown correctly at page 4, line 11, of the Amendment filed on April 19, 2007).

(3) In column 103, at line 54, "tat" should read "that" (shown correctly at page 5, line 8, of the Amendment filed on April 19, 2007).

(4) In column 103, at line 63, "a" should read "o" (shown correctly at page 5, line 10, of the Amendment filed on April 19, 2007).

(5) In column 103, at line 66, "wit" should read "with" (shown correctly at page 5, line 12, of the Amendment filed on April 19, 2007).

(6) In column 104, at line 2, "-C(O)Q(1-4C)alkyl" should read "-C(O)O(1-4C)alkyl" (shown correctly at page 5, line 13, of the Amendment filed on April 19, 2007).

(7) In column 104, at line 3, "trifluorometihyl" should read "trifluoromethyl" (shown correctly at page 5, line 14, of the Amendment filed on April 19, 2007).

(8) In column 104, at line 15, "subsfituents" should read "substituents" (shown correctly at page 6, line 3, of the Amendment filed on April 19, 2007).

(9) In column 104, at line 17, "-S(Q)2-(1-4C)alkyl" should read "-S(O)₂-(1-4C)alkyl" (shown correctly at page 6, line 4, of the Amendment filed on April 19, 2007).

b. Applicant Mistakes – 37 C.F.R. §1.322

(1) In column 102, at line 50, "substitutents" should read "substituents". This is a typographical error.

(2) In column 103, at line 7, "substitutents" should read "substituents". This is a typographical error.

These mistakes occurred in good faith and correction of these mistakes is not believed to involve a change in the patent that would constitute new matter or that would require re-examination.

B. Fee Payment

The Director is authorized to charge the requisite fee under §1.20(a) and any other necessary fees, and to credit any overpayments, to Deposit Account No. 50-0344 in the name of Theravance, Inc.

C. Mailing Address for Certificate

The certificate of correction should be sent to:

Jeffrey A. Hagenah, Ph.D.
Theravance, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080

Any questions regarding this paper should be addressed to the undersigned attorney for assignee.

Respectfully submitted,
THERAVANCE, INC.

Date: February 3, 2009

/Jeffrey A. Hagenah/
Jeffrey A. Hagenah, Ph.D.
Reg. No. 35,175
(650) 808-6406

Correspondence Address:

THERAVANCE, INC.
Attn: Patent Dept.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000; Fax: (650) 808-6078

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 1 of 1

PATENT NO. : 7,317,102 B2

APPLICATION NO.: 10/813,745

ISSUE DATE : January 8, 2008

INVENTOR(S) : Mathai Mammen et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 102

at line 50, "substitutents" should read "substituents"

Column 103

at line 7, "substitutents" should read "substituents".

at line 17, delete "of any one"

at line 27, "-(CH₂)₈-" should read "-(CH₂)₈"

at line 54, "tat" should read "that"

at line 63, "a" should read "o"

at line 66, "wit" should read "with"

Column 104

at line 2, "-C(O)Q(1-4C)alkyl" should read "-C(O)O(1-4C)alkyl"

at line 3, "trifluoromethyl" should read "trifluoromethyl"

at line 15, "subsfituents" should read "substituents"

at line 17, "-S(Q)2-(1-4C)alkyl" should read "-S(O)₂-(1-4C)alkyl"

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Theravance, Inc. - Patent Department
901 Gateway Blvd.
South San Francisco, CA 94080

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.